DPP-4 inhibitors lower HbA1c by blocking the enzyme that breaks down incretin hormones, helping the body regulate blood sugar more effectively in type 2 diabetes. Also known as gliptins, this class of oral medicines includes sitagliptin, linagliptin, and vildagliptin, and is widely used across NHS clinical practice. Understanding how much gliptins reduce HbA1c, how they compare with other antidiabetic agents, and what safety considerations apply is essential for both patients and prescribers. This article outlines the evidence base, NICE guidance, and practical factors that influence glycaemic response.

How DPP-4 Inhibitors Work to Reduce Blood Sugar Levels

DPP-4 inhibitors block the enzyme that degrades incretin hormones GLP-1 and GIP, increasing insulin secretion and reducing glucagon release in a glucose-dependent manner, which limits hypoglycaemia risk when used alone or with metformin.

Have any more questions about this? Message our pharmaceutical team to get more info →

DPP-4 inhibitors — also known as gliptins — are a class of oral medicines used in the management of type 2 diabetes mellitus. They work by blocking the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for breaking down incretin hormones, particularly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting this enzyme, gliptins allow these hormones to remain active in the bloodstream for longer.

The prolonged activity of incretin hormones produces two key effects that help lower blood glucose levels:

• Increased insulin secretion from the pancreatic beta cells in response to meals

• Reduced glucagon release from pancreatic alpha cells, which limits unnecessary glucose production by the liver

Because these effects are glucose-dependent — meaning they are most pronounced when blood sugar is already elevated — DPP-4 inhibitors carry a relatively low risk of hypoglycaemia when used alone or with metformin. However, this risk increases when a gliptin is combined with a sulfonylurea or insulin; in such cases, a reduction in the sulfonylurea or insulin dose may be needed, and patients should be counselled on recognising and managing hypoglycaemia.

It is important to note that DPP-4 inhibitors should not be used in combination with GLP-1 receptor agonists, as both drug classes act on the same incretin pathway and concurrent use is not supported by evidence or current guidance.

Commonly prescribed DPP-4 inhibitors in the UK include sitagliptin, saxagliptin, alogliptin, linagliptin, and vildagliptin. All are available as oral tablets and are generally taken once or twice daily, depending on the specific agent. They are typically used alongside dietary modification and other antidiabetic medicines as part of a broader management plan.

Expected HbA1c Reductions With DPP-4 Inhibitor Treatment

DPP-4 inhibitors typically reduce HbA1c by 0.5–1.0% (approximately 5.5–11 mmol/mol); greater reductions occur in patients with higher baseline HbA1c, and response should be assessed after three months per NICE NG28.

HbA1c — glycated haemoglobin — is the primary marker used to assess long-term blood glucose control in people with type 2 diabetes. It reflects average blood sugar levels over the preceding two to three months and is expressed as a percentage or in mmol/mol. Reducing HbA1c is a central goal of diabetes management, as sustained elevated levels are associated with an increased risk of microvascular and macrovascular complications.

Clinical trials and meta-analyses consistently show that DPP-4 inhibitors produce a modest but clinically meaningful reduction in HbA1c, typically in the range of:

• 0.5% to 1.0% (approximately 5.5 to 11 mmol/mol) when used as monotherapy or add-on therapy

• Reductions at the higher end of this range are more likely when baseline HbA1c is significantly elevated

For example, sitagliptin has demonstrated reductions of around 0.6–0.8% in randomised controlled trials, while vildagliptin and saxagliptin show broadly comparable efficacy. These reductions are generally considered moderate — sufficient to contribute meaningfully to glycaemic targets, but less potent than agents such as GLP-1 receptor agonists or SGLT-2 inhibitors in head-to-head comparisons.

Individual responses vary. Patients with higher baseline HbA1c values tend to experience greater absolute reductions. In line with NICE NG28, HbA1c should be rechecked approximately three months after initiating or changing therapy to evaluate response. Once stable, monitoring every three to six months is appropriate, reducing to six-monthly when control is well established. If HbA1c targets are not met after an adequate trial, treatment should be reviewed and intensified in line with agreed individual targets and NICE guidance.

Comparing DPP-4 Inhibitors to Other Type 2 Diabetes Medicines

DPP-4 inhibitors produce moderate HbA1c reductions and are weight-neutral, but are less potent than GLP-1 receptor agonists and SGLT-2 inhibitors, which also offer cardiovascular and renal protective benefits not seen with gliptins.

When considering how DPP-4 inhibitors lower HbA1c relative to other antidiabetic agents, it is helpful to place them within the broader landscape of type 2 diabetes pharmacotherapy. Metformin remains the first-line agent recommended by NICE NG28, typically achieving HbA1c reductions of 1.0–1.5% (11–16 mmol/mol), making it more potent than gliptins as a standalone treatment.

Compared with other second-line options, DPP-4 inhibitors occupy a middle ground:

• SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) offer similar or slightly greater HbA1c reductions alongside additional cardiovascular and renal benefits. NICE NG28 recommends prioritising SGLT-2 inhibitors in people with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease — often alongside or instead of metformin — due to these organ-protective effects

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide) generally produce greater HbA1c reductions (1.0–1.5%) and significant weight loss, but are injectable and more costly. DPP-4 inhibitors must not be used concurrently with GLP-1 receptor agonists

• Sulfonylureas (e.g., gliclazide) can achieve comparable or greater HbA1c reductions but carry a higher risk of hypoglycaemia and weight gain. When a DPP-4 inhibitor is added to a sulfonylurea regimen, the sulfonylurea dose may need to be reduced

• Pioglitazone offers similar glycaemic efficacy to gliptins but is associated with fluid retention and fracture risk

DPP-4 inhibitors are generally considered weight-neutral, which is an advantage over sulfonylureas and insulin. They are also well tolerated and have a favourable safety profile in older adults and those with renal impairment (with appropriate dose adjustment). However, unlike SGLT-2 inhibitors and GLP-1 receptor agonists, they have not demonstrated significant cardiovascular or renal protective benefits beyond glucose lowering, which is an important consideration in patients with established cardiovascular disease.

NICE Guidelines on Using DPP-4 Inhibitors in Type 2 Diabetes

NICE NG28 recommends DPP-4 inhibitors as second- or third-line therapy alongside metformin, particularly when hypoglycaemia risk or weight gain is a concern, but prioritises SGLT-2 inhibitors in patients with cardiovascular disease or chronic kidney disease.

The National Institute for Health and Care Excellence (NICE) provides detailed guidance on the use of DPP-4 inhibitors in type 2 diabetes through its guideline NG28 (Type 2 diabetes in adults: management), most recently updated in 2022. NICE recommends a structured, stepwise approach to pharmacological management, with metformin as the cornerstone of first-line therapy in most patients.

Where metformin is contraindicated or not tolerated, a DPP-4 inhibitor may be considered as monotherapy. More commonly, DPP-4 inhibitors are recommended as an option at second-line or third-line therapy in combination with metformin, when blood glucose remains inadequately controlled. Specifically, NICE suggests considering a DPP-4 inhibitor as a second agent when:

• The patient has a high risk of hypoglycaemia (making sulfonylureas less suitable)

• Weight management is a concern and a sulfonylurea's weight-gaining effects are undesirable

• An SGLT-2 inhibitor is contraindicated or not tolerated

NICE NG28 recommends that in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, an SGLT-2 inhibitor should generally be prioritised — often alongside or instead of metformin — due to its organ-protective benefits. DPP-4 inhibitors remain a valid option where SGLT-2 inhibitors and GLP-1 receptor agonists are not appropriate, but should not be prescribed alongside a GLP-1 receptor agonist.

From a renal perspective, renal dosing thresholds vary between individual agents and prescribers must consult the relevant Summary of Product Characteristics (SmPC) for each medicine. As a general principle, most DPP-4 inhibitors require dose reduction or avoidance in moderate-to-severe renal impairment; linagliptin is an exception, as it is primarily excreted via the bile and does not require renal dose adjustment. Hepatic impairment is also relevant: vildagliptin, for example, should be avoided in patients with hepatic impairment, and liver function tests (LFTs) should be monitored during treatment as specified in its SmPC. Prescribers should consult the SmPC and NICE NG28 when initiating treatment in patients with renal or hepatic impairment.

Factors That Affect How Well DPP-4 Inhibitors Lower HbA1c

Baseline HbA1c is the strongest predictor of response; longer diabetes duration, reduced beta-cell function, poor adherence, and lifestyle factors can all diminish the glycaemic effect of DPP-4 inhibitors.

The degree to which DPP-4 inhibitors lower HbA1c is not uniform across all patients. Several clinical and patient-related factors influence the magnitude of glycaemic response, and understanding these can help set realistic expectations and guide treatment decisions.

Baseline HbA1c is one of the strongest predictors of response. Patients with higher starting HbA1c values (e.g., above 75 mmol/mol or 9%) tend to experience greater absolute reductions, although their levels may still remain above target. Conversely, patients who are already close to their glycaemic target may see only modest numerical improvements.

Other important factors include:

• Duration of diabetes: Longer disease duration is associated with greater beta-cell dysfunction, which may reduce the incretin-based response to DPP-4 inhibition

• Residual beta-cell function: As DPP-4 inhibitors rely on stimulating endogenous insulin secretion, patients with significantly impaired beta-cell reserve may respond less well

• Adherence to treatment: Consistent daily dosing is essential; missed doses reduce the sustained inhibition of DPP-4 and blunt glycaemic control

• Concomitant medications: Combining a DPP-4 inhibitor with metformin or an SGLT-2 inhibitor generally produces additive HbA1c reductions

• Lifestyle factors: Diet, physical activity, and body weight all influence overall glycaemic control and can either enhance or diminish the pharmacological effect of gliptins

Regular HbA1c monitoring — approximately three months after initiating or adjusting treatment, then every three to six months until stable, and six-monthly thereafter — is recommended in line with NICE NG28 to assess ongoing response. If HbA1c targets are not met after an adequate trial, treatment should be reviewed and switched or intensified in accordance with individually agreed targets and current NICE guidance.

Side Effects and Safety Considerations for Patients

DPP-4 inhibitors are generally well tolerated, but important risks include pancreatitis, bullous pemphigoid, severe joint pain, and increased heart failure hospitalisation risk with saxagliptin and alogliptin; they are not recommended in pregnancy.

DPP-4 inhibitors are generally well tolerated, and their favourable safety profile is one reason they are widely used in clinical practice. However, as with all medicines, patients should be aware of potential adverse effects and know when to seek medical advice.

Common side effects include:

• Nasopharyngitis and upper respiratory tract infections — the most frequently reported adverse effects (mechanism not fully established)

• Headache and dizziness — reported in some patients, particularly during the initial weeks of treatment

• Gastrointestinal symptoms — such as nausea or constipation, though these are generally mild

Less common but important safety considerations include:

• Hypoglycaemia: Although the risk is low when a gliptin is used alone or with metformin, it increases when combined with a sulfonylurea or insulin. Patients should be counselled on hypoglycaemia symptoms, and a reduction in sulfonylurea or insulin dose should be considered

• Pancreatitis: Post-marketing reports of acute pancreatitis have been associated with DPP-4 inhibitors. The MHRA has issued guidance on this risk. Patients should seek urgent medical attention if they develop severe, persistent abdominal pain. Prescribers should exercise caution in patients with a history of pancreatitis

• Heart failure: The MHRA has highlighted that saxagliptin and alogliptin have been associated with a possible increased risk of hospitalisation for heart failure; these agents should be used with caution in patients with existing cardiac conditions

• Bullous pemphigoid: A rare skin blistering condition has been reported with long-term use of some gliptins, as noted in MHRA safety communications. If suspected, the medicine should be stopped and specialist advice sought

• Serious hypersensitivity reactions: Rare but serious reactions including angioedema and severe skin reactions have been reported. Patients should seek urgent medical attention if they develop swelling of the face, lips, tongue or throat, difficulty breathing, or a severe skin rash

• Joint pain (arthralgia): The MHRA and EMA have highlighted reports of severe and disabling joint pain; patients experiencing new or worsening joint symptoms should inform their GP or diabetes team

• Hepatic effects: Vildagliptin should be avoided in patients with hepatic impairment, and liver function tests should be monitored during treatment as specified in its SmPC. Prescribers should check the relevant SmPC for hepatic guidance for each agent

Use in pregnancy and breastfeeding: DPP-4 inhibitors are not recommended during pregnancy or breastfeeding, as data on safety in these situations are limited. Women who are planning a pregnancy or who become pregnant should seek specialist advice promptly; insulin is generally the preferred treatment for managing blood glucose during pregnancy.

Patients should contact their GP or diabetes team if they experience any unusual symptoms, particularly abdominal pain, skin changes, joint pain, or signs of infection. DPP-4 inhibitors should not be used in type 1 diabetes or diabetic ketoacidosis.

If you think you have experienced a side effect from a DPP-4 inhibitor, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting suspected adverse reactions helps the MHRA monitor the ongoing safety of medicines used in the UK.

Frequently Asked Questions